For the 116 million chronic pain sufferers in the US, NavegaPN7 is a sophisticated gene therapy for pain relief. Unlike conventional painkillers, the Navega therapy is highly specific to the pain source, it is non-addictive, and provides months of relief.
Active Companies
https://navegatx.com/en
IGE Technology Accelerator
NSF I-Corps
Technology Management and Entrepreneurism Certificate Program
Funds: $50,000
Navega Therapeutics was featured in a special issue of Phramafile which dedicated this edition to pain management.
Navega received two SBIR Phase I Grants from the NIH under NINDS, as part of the NIH HEAL Initiative, and under the NCI, totaling in $1.1 million in funding.
Co-Founder, Ana Moreno, was recognized at the national TechConnect Defense Conference.